Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a …
…, M Murakami, H Horn, E Leich, AA Moccia… - The lancet …, 2015 - thelancet.com
Background Follicular lymphoma is a clinically and genetically heterogeneous disease, but
the prognostic value of somatic mutations has not been systematically assessed. We aimed …
the prognostic value of somatic mutations has not been systematically assessed. We aimed …
Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma
…, E Cupelli, L Ceriani, AA Moccia… - Blood, The Journal …, 2018 - ashpublications.org
The rarity of neoplastic cells in the biopsy imposes major technical hurdles that have so far
limited genomic studies in classical Hodgkin lymphoma (cHL). By using a highly sensitive …
limited genomic studies in classical Hodgkin lymphoma (cHL). By using a highly sensitive …
[PDF][PDF] International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era
AA Moccia, J Donaldson, M Chhanabhai… - Journal of clinical …, 2012 - scholar.archive.org
Purpose The International Prognostic Score (IPS) is the most widely used risk stratification
index for Hodgkin’s lymphoma (HL). It is based on patients treated before 1992 and predicts 5-…
index for Hodgkin’s lymphoma (HL). It is based on patients treated before 1992 and predicts 5-…
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial
…, A Hüttmann, M Wilhelm, JM Zijlstra, A Moccia… - The Lancet …, 2021 - thelancet.com
Background Combined-modality treatment consisting of chemotherapy and consolidation
radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin lymphoma. …
radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin lymphoma. …
The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC cancer agency and the lymphoma study association
…, D Canioni, P Farinha, S Boussetta, AA Moccia… - Clinical Cancer …, 2015 - AACR
Purpose: We aimed to assess the prognostic significance of follicular lymphoma–associated
macrophages in the era of rituximab treatment and maintenance. Experimental Design: We …
macrophages in the era of rituximab treatment and maintenance. Experimental Design: We …
Incidence, risk factors and outcome of histological transformation in follicular lymphoma
…, PMV Rancoita, A Stathis, AA Moccia… - British journal of …, 2012 - Wiley Online Library
Histological transformation ( HT ) into diffuse large B‐cell lymphoma ( DLBCL ) was documented
in 37 of the 281 (13%; 95% CI , 9–18) follicular lymphoma ( FL ) patients treated at our …
in 37 of the 281 (13%; 95% CI , 9–18) follicular lymphoma ( FL ) patients treated at our …
Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma
CL Freeman, R Kridel, AA Moccia… - Blood, The Journal …, 2019 - ashpublications.org
Despite widespread use of bendamustine and rituximab (BR) as frontline therapy for
advanced-stage follicular lymphoma (FL), little is known about the risk of early progression or …
advanced-stage follicular lymphoma (FL), little is known about the risk of early progression or …
Genetic and phenotypic attributes of splenic marginal zone lymphoma
…, V Meignin, M Merli, A Moccia… - Blood, The Journal …, 2022 - ashpublications.org
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity.
The clinical course is variable, multiple genes are mutated with no unifying mechanism, and …
The clinical course is variable, multiple genes are mutated with no unifying mechanism, and …
Metabolic tumor volume for response prediction in advanced-stage Hodgkin lymphoma
18 F-FDG PET/CT for staging Hodgkin lymphoma may allow for accurate and reliable assessment
of the metabolic tumor volume (MTV) as a baseline risk factor. Our aim was to analyze …
of the metabolic tumor volume (MTV) as a baseline risk factor. Our aim was to analyze …
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
…, H Goergen, I Buehnen, C Kobe, A Moccia… - The Lancet …, 2021 - thelancet.com
Background The German Hodgkin Study Group's HD18 trial established the safety and
efficacy of PET-guided eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, …
efficacy of PET-guided eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, …